Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by First Trust Advisors LP

First Trust Advisors LP lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 34.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 188,161 shares of the pharmaceutical company’s stock after selling 99,731 shares during the period. First Trust Advisors LP’s holdings in Vertex Pharmaceuticals were worth $73,691,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of VRTX. Chesapeake Asset Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 33 shares during the last quarter. Colonial Trust Co SC raised its position in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 38 shares in the last quarter. Total Investment Management Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $33,000. Financial Network Wealth Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 50.9% in the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock valued at $34,000 after acquiring an additional 29 shares during the period. Finally, Y.D. More Investments Ltd lifted its holdings in Vertex Pharmaceuticals by 345.0% in the third quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim results: The company said a pre‑specified Week‑36 interim analysis of the Phase 3 RAINIER trial of povetacicept met the primary objective and all secondary endpoints, citing meaningful efficacy vs. placebo in adults with IgA nephropathy — the core catalyst driving the move. Business Wire release
• Positive Sentiment: Analyst reinforcement: William Blair’s Myles Minter reiterated a Buy and said confidence in povetacicept’s profile has increased after the RAINIER readout, strengthening the bullish investment case for VRTX. Analyst backing amplifies the positive reaction. TipRanks/William Blair note
• Positive Sentiment: Perception of high commercial potential: Coverage notes that povetacicept — acquired in a multibillion‑dollar deal — could be a best‑in‑class therapy in a competitive kidney disease market, supporting a longer‑term revenue upside if full data and approvals follow. BioPharmaDive article
• Neutral Sentiment: Market reaction and headlines: Media and trading outlets reported a sharp after‑hours/share surge following the announcement; that immediate momentum reflects sentiment but may be volatile as investors digest details and next steps. Benzinga coverage
• Negative Sentiment: Ongoing uncertainty: These are interim results from an ongoing trial — final RAINIER readout, safety follow‑up, regulatory timelines and payer/commercial execution remain unknown. Investors should weigh upside against the risk that final data or regulatory review could change the outlook. Yahoo Finance release

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 58,613 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president owned 58,934 shares in the company, valued at $27,630,027.22. This represents a 49.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the completion of the transaction, the executive vice president directly owned 37,725 shares in the company, valued at $17,391,225. This represents a 20.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 91,156 shares of company stock valued at $42,845,497. Insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VRTX. Stifel Nicolaus raised their price objective on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Evercore boosted their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Leerink Partners raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $542.00.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $460.87 on Tuesday. The company has a market cap of $117.07 billion, a price-to-earnings ratio of 30.06 and a beta of 0.31. The stock has a 50 day simple moving average of $467.50 and a 200-day simple moving average of $435.79. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.98 EPS. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.